Posted on 4/1/19
Mustang Bio Announces $20 Million Venture Debt Financing Agreement with Horizon Technology Finance
NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene . . .
Posted on 4/1/19
SpringWorks Therapeutics Completes $125 Million Series B Financing
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer
Posted on 4/1/19
Thoughts On A Post-Merger Bristol-Myers Squibb: Scaling From Celgene To Buy BMS
Summary CELG appears to be about to become a BMY asset, based on end-of-week news flow. The surge in CELG shares and drop in BMY below . . .
Posted on 4/1/19
Better Buy: AbbVie vs. Johnson & Johnson
AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) together market one of the top cancer drugs in the world, Imbruvica. But while the two companies are partners . . .
Posted on 4/1/19
Actinium Completes Second Module of Collaborative Research Program with Astellas
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced today that it has successfully completed the second module of its previously announced research and option agreement with Astellas . . .
Posted on 4/1/19
Peach & Lily Partners With Ulta Beauty
Pioneering skin-care brand, Peach & Lily, today announced the expansion of its cult-favorite skincare collection from 250 locations to all Ulta Beauty stores nationwide. Peach & . . .
Posted on 3/31/19
Tyme Technologies Prices $12 Million Registered Offering
NEW YORK, March 29, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME) announced today that it has priced a registered offering of 8 million shares . . .
Posted on 3/29/19
Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks?
Biogen's (NASDAQ:BIIB) bid to reshape Alzheimer's disease treatment was delivered a big blow last week when it decided to bail on its once-promising Alzheimer's drug aducanumab. . . .
Posted on 3/28/19
Advaxis Announces Reverse Stock Split
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that its Board of Directors . . .
Posted on 3/28/19
Mitsubishi Tanabe Pharma America Announces Collaboration With Massachusetts General Hospital On ALS Biomarker Study
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced a collaboration with the Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) to conduct a study designed . . .
Posted on 3/28/19
Satisfi Labs Completes New Funding Round
Satisfi Labs, an AI-powered Knowledge Management Platform, today announced it has completed a new round of funding led by Major League Baseball (MLB) with participation from . . .
Posted on 3/28/19
GenScript to Fund Generation of First Sustainable Drosophila Antibody Library
GenScript, the world's leading gene synthesis provider, announced today that it will provide funding and DNA synthesis expertise toward a project at Harvard University to generate . . .
Posted on 3/27/19
Johnson & Johnson Vs. Pfizer: Which Big Pharma Giant Is The Better Dividend Stock?
SummaryJohnson & Johnson and Pfizer are both mega-cap healthcare stocks that pay dividends to shareholders.However, they have somewhat different business models, and have different dividend yields . . .
Posted on 3/26/19
Legal Battle Against Opioid Crisis Heats Up
Oklahoma Attorney General Mike Hunter will hold a press conference today to announce a "breaking development" in a multibillion-dollar lawsuit accusing OxyContin maker Purdue Pharma, J&J . . .
Posted on 3/26/19
Celgene/Bristol-Myers Merger: The Arb Spread Continuum Offers Clues
Summary Uncertainty around the proposed Bristol-Myers/Celgene merger remains elevated as several institutional investors lobby against the deal. It's nearly impossible to discern the outcome by reading . . .
Posted on 3/26/19
Celgene's Shareholders, Not Bristol-Myers Squibb's, Should Reject The Deal
Summary Proposed deal deeply undervalues Celgene, and BMS admits it. Celgene’s pipeline is about to turn a corner with potentially 5 product launches in the next . . .
Posted on 3/25/19
New York Financial Industries Dinner Breaks Record, Raising More Than $720K for National Jewish Health
Thomas A. Greco of Hilco Global HonoredDoug Jung (left) presents the National Jewish Health Humanitarian Award to Thomas Greco, CEO of Hilco Valuation and Industries Services, . . .
Posted on 3/25/19
Bristol-Myers Squibb Board Sends Letter to Shareholders Regarding Merger With Celgene
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company’s (NYSE:BMY) Board of Directors today sent an open letter to the Company’s shareholders regarding the previously announced definitive merger agreement with . . .
Posted on 3/25/19
Integrated Dermatology Enters New York
BOCA RATON, Fla.--(BUSINESS WIRE)--Integrated Dermatology, the largest independent dermatology practice in the United States, is opening its first location in New York with the addition of . . .
Posted on 3/25/19
2019’s Best & Worst States for Doctors – WalletHub Study
Doctors are among the highest-paid and most educated professionals in the U.S. In fact, “physician” was the highest-paid job type in 2018, with a median base . . .
Posted on 3/25/19
Merck Portfolio: Halftime Report
SummaryAfter the success of a hedged portfolio built around an AT&T position in 2017, I started presenting similar portfolios built around other conservative stocks, including Merck . . .
Posted on 3/25/19
Pfizer Steps Further In The Door For Gene Therapies
SummaryPfizer takes 15% stake in privately held french gene therapy biotech Vivet Therapeutics, with the exclusive option to eventually acquire it.The first gene therapy product VTX-801 . . .
Posted on 3/25/19
Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals
Rare diseases have proven to be gold mines for Vertex Pharmaceuticals (NASDAQ:VRTX)and Regeneron Pharmaceuticals (NASDAQ:REGN). Vertex's market cap of nearly $47 billion and Regeneron's market cap . . .
Posted on 3/25/19
Better Buy: Verizon vs. Johnson & Johnson
Verizon Communications (NYSE:VZ) and Johnson & Johnson (NYSE:JNJ) might seem like an odd pairing, but they actually have a lot in common. They both hold commanding . . .
Posted on 3/25/19
Teladoc Health To Acquire MedecinDirect For French Telemedicine
Teladoc Health (TDOC) announced it has agreed to acquire MedecinDirect for an undisclosed amount.

